A technique for size-selective discrimination of protein analytes was developed by incorporating poly(ethylene glycol) (PEG) lipopolymers into supported lipid bilayers. The membranes also contained biotinylated lipids, which recognized both streptavidin and anti-biotin IgG. By employing various PEG lipopolymer concentrations, clear discrimination against anti-biotin (Mw = 150 000 Da) binding could be observed, which became more pronounced at higher polymer densities. On the other hand, streptavidin (Mw = 52 800) binding to the membrane remained unaffected even at PEG concentrations that were well into the mushroom-to-brush phase transition. These observations were exploited to create an on-chip ligand-receptor binding assay that favored streptavidin binding over anti-biotin by several orders of magnitude in the presence of the lipopolymer. Control experiments revealed that the two proteins are bound to similar extents from a multi-protein analyte solution in the absence of PEG.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2548332 | PMC |
| http://dx.doi.org/10.1021/ja062010r | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipopolymer/siRNA Nanoparticles Targeting the Signal Transducer and Activator of Transcription 5A Disrupts Proliferation of Acute Lymphoblastic Leukemia.
ACS Pharmacol Transl Sci
September 2024
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada.
Article Synopsis
- The delivery of small interfering RNAs (siRNAs) for gene-targeted therapies faces challenges due to their inability to penetrate cell membranes, especially in lymphocytes.
- A novel lipid-conjugated polyethylenimine lipopolymer platform was developed to enhance the delivery of siRNAs, forming stable complexes called lipopolymer nanoparticles (LPNPs).
- Tests in both human blood cells and acute lymphoblastic leukemia models showed that LPNPs effectively silenced specific genes, induced cancer cell death, and reduced tumor sizes while maintaining a safe profile without triggering inflammatory responses.
Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia.
Acta Biomater
October 2024
Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, Alberta, Canada; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. Electronic address:
Approximately 25% of newly diagnosed AML patients display an internal tandem duplication (ITD) in the fms-like tyrosine kinase 3 (FLT3) gene. Although both multi-targeted and FLT3 specific tyrosine kinase inhibitors (TKIs) are being utilized for clinical therapy, drug resistance, short remission periods, and high relapse rates are challenges that still need to be tackled. RNA interference (RNAi), mediated by short interfering RNA (siRNA), presents a mechanistically distinct therapeutic platform with the potential of personalization due to its gene sequence-driven mechanism of action.
View Article and Find Full Text PDFSurface modification of extracellular vesicles with polyoxazolines to enhance their plasma stability and tumor accumulation.
Biomaterials
February 2025
ICGM, Montpellier University, CNRS, ENSCM, Montpellier, France; Institut Universitaire de France (IUF), Paris, France. Electronic address:
Extracellular vesicles (EVs) are future promising therapeutics, but their instability in vivo after administration remains an important barrier to their further development. Many groups evaluated EV surface modification strategies to add a targeting group with the aim of controlling EV biodistribution. Conversely, fewer groups focused on their stabilization to obtain "stealth" allogenic EVs.
View Article and Find Full Text PDFLipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models.
J Control Release
March 2024
Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton T6G 1H9, Alberta, Canada; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton T6G 2H1, Alberta, Canada. Electronic address:
The clinical development of tyrosine kinase inhibitors (TKI) has led to great strides in improving the survival of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) patients. But even the new generation TKIs are rendered futile in the face of evolving landscape of acquired mutations leading to drug resistance, necessitating the pursuit of alternative therapeutic approaches. In contrast to exploiting proteins as targets like most conventional drugs and TKIs, RNA Interference (RNAi) exerts its therapeutic action towards disease-driving aberrant genes.
View Article and Find Full Text PDFTuning the Potency of Farnesol-Modified Polyethylenimine with Polyanionic Trans-Booster to Enhance DNA Delivery.
ACS Biomater Sci Eng
March 2024
Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, Alberta T6G 1H9, Canada.
Article Synopsis
- Low molecular weight polyethylenimine (PEI) based lipopolymers are being studied as nonviral carriers for gene therapy, showing good DNA binding and cellular uptake.
- Despite their promising features, the specific polymer developed (PEI1.2k-SA-Far7) struggled to achieve strong transfection in cell cultures on its own.
- The addition of a commercial additive called Trans-Booster improved the transfection efficiency of the polyplexes, making them as effective as established reagents while maintaining cell compatibility and low toxicity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!